TABLE 2.
Rationale for novel drug and oncologist prescribing patterns for the 133 novel drugs prescribed in this study
| Novel drug rationale (N = 133) | N (%) |
|---|---|
| Genomic result | 44 (33.1) |
| Unclear | 23 (17.3) |
| Conventional treatment failure | 18 (13.5) |
| External opinion | 10 (7.5) |
| Acute deterioration | 7 (5.3) |
| Evidence cited | 7 (5.3) |
| Pharmacological therapy preferred | 4 (3.0) |
| Ineligible for clinical trial | 4 (3.0) |
| Parental choice | 3 (2.3) |
| Prior clinical use | 3 (2.3) |
| Combination to prevent resistance | 2 (1.5) |
| Steroid sparing therapy | 2 (1.5) |
| CAR‐T Cell Anergy | 1 (0.8) |
| Treatment continuation | 1 (0.8) |
| Required treatment intensification | 1 (0.8) |
| Loss of major molecular response post transplant | 1 (0.8) |
| Radiation necrosis | 1 (0.8) |
| Recommended for Bleeding Syrinx | 1 (0.8) |
| Prescribing oncologist (Employment status, Specialization) | N (% per oncologist) |
|---|---|
| Oncologist 1 (Full‐time, brain and solid tumors) | 38 (28.6) |
| Oncologist 2 (Full‐time, brain and solid tumors) | 18 (13.5) |
| Oncologist 3 (Full‐time, brain and solid tumors) | 15 (11.3) |
| Oncologist 4 (Full‐time, brain and solid tumors) | 14 (10.5) |
| Oncologist 5 (Full‐time, hematological malignancies) | 9 (6.8) |
| Oncologist 6 (Part‐time, solid tumors) | 6 (4.5) |
| Oncologist 7 (Full‐time, hematological malignancies) | 6 (4.5) |
| Oncologist 8 – 17 b | <5 a (<3.8) |
a
Twenty seven drugs prescribed in total.
b
Oncologists 8‐17 included five full‐time and five part‐time oncologists; seven who specialize in brain and solid tumors and three who specialize in hematological malignancies.